A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome

AIDS

Volumn 14, Issue 3, 2000, Pages

  Carr, Andrew ^a   Miller, John ^b   Matthew, Law ^b   Cooper, David A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HIV; Hyperlipidaemia; Insulin resistance; Lactic acidaemia; Lipodystrophy; Mitochondrial toxicity; Wasting

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CHOLESTEROL; DIDANOSINE; GLUCOSE; INDINAVIR; INSULIN; LACTIC ACID; LAMIVUDINE; LIVER ENZYME; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL DISTENSION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY COMPOSITION; BODY FAT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTATE BLOOD LEVEL; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; NAUSEA; OBESITY; OUTPATIENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIPODYSTROPHY; LIVER; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0034008520     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200002180-00001     Document Type: Article

References (14)

1. 1. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
2. 2. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
3. 3. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
4. 4. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chisholm DJ, Cooper DA. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus. Lancet 1999, 353:2893-2899.
5. 5. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-472.
6. 6. Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:228-237.
7. 7. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13: 1659-1667.
8. 8. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JAM, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998, 12:1735-1744.
9. 9. Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med 1992, 20:80-93.
10. 10. Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta 1995, 1271: 275-280.
11. 11. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine with and without hydroxyurea for HIV infection. AIDS 1998, 12:F71-F77.
12. 12. Hackney AC, Hezier W, Gulledge TP, et al. Effects of hydroxyurea administration on the body weight, body composition and exercise performance of patients with sickle-cell anaemia. Clin Science 1997, 92:481-486.
13. 13. Markovic TP, Campbell LV, Balasubramanian S, et al. Beneficial effect on average lipid levels from energy restriction and fat loss in obese individuals with or without type 2 diabetes. Diabetes Care 1998, 21:695-700.
14. 14. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA panel. JAMA 1998, 280:78-86.